Navigation Links
Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting
Date:4/10/2008

d circumstances.

Forward-looking statements involve risks and uncertainties, including risks and uncertainties related to Oncothyreon's business and the general economic environment. Many of these risks and uncertainties are beyond Oncothyreon's control. These risks, uncertainties and other factors could cause our actual results to differ materially from those projected in forward-looking statements. Risks, uncertainties, and assumptions include those predicting the timing, duration and results of clinical trials, the timing and results of regulatory reviews, and the safety and efficacy of PX-12 and PX-866. There can be no guarantee that the results of preclinical studies or of early clinical trials will be predictive of either safety or efficacy in future clinical trials. These and other risks and uncertainties are described in the reports and other documents filed by Oncothyreon Inc. with the SEC and/or Canadian regulatory authorities.

Although Oncothyreon believes that any forward-looking statements contained herein are reasonable, it can give no assurance that its expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of the risks and uncertainties associated with Oncothyreon, you are encouraged to review the official corporate documents filed with the securities regulators in the United States on U.S. EDGAR and in Canada on SEDAR. Oncothyreon is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.


'/>"/>
SOURCE Oncothyreon Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncothyreon announces effectiveness of shelf registration statement
2. Oncothyreon announces issuance of patent for PX-867
3. Oncothyreon to present at upcoming investment conferences
4. Oncothyreon reports full year and fourth quarter 2007 financial results
5. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
6. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
7. Oncothyreon launches new corporate website
8. Oncothyreon to present at BIO CEO & Investor Conference
9. Oncothyreon highlights corporate and clinical objectives for 2008
10. Biomira announces plan to change name to Oncothyreon
11. Medicsight Announces Chinese State Food and Drug Administration Approval for MedicRead Colon Workstation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)...  Decision Resources Group finds that the majority ... the United States believe that ... be the level of savings achievable by their ... cost to patients. Payers plan to leverage preferential ... expectations in order to encourage physician prescribing of ...
(Date:7/30/2014)... July 30, 2014 A study presented ... safety and efficacy of CSL Behring,s C1 Inhibitor ... transplants in highly sensitized patients. C1-INH is a ... complement system. The study shows that ... in the levels of complement components 3 and ...
(Date:7/30/2014)... Chicago Bears are excited to announce the team,s partnership ... effort to raise awareness of skin cancer. Through this ... skin cancer screenings at a preseason fan event on ... me™ is an educational campaign designed to inform the public, ... cancer, and encourages people to get screened by a ...
(Date:7/30/2014)... LONDON , July 30, 2014  Replikins Ltd. ... structure of the Ebola virus. Before the current outbreaks, ... Replikins per 100 amino acids) between 1995 and 2002 ... 2010, threefold in 2012, and sixteen-fold in 2013, thus ... the past, this technology has been shown to be ...
Breaking Biology Technology:Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 3Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 2Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 3Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 4
... such tests on samples sent in from all over Spain. ... truly personalised medicine. And researchers are exploring new ways to ... scale: the genes that are being read or transcribed; the ... the length of the telomeres capping its chromosomes. The ...
... or ultracapacitors, differ from regular capacitors that you would ... store substantially higher amounts of charges. They have garnered ... discharge faster than batteries, yet they are still limited ... energy density of batteries. An EC that combines the ...
... March 16, 2012  Tarsa Therapeutics, Inc. today announced ... financing led by new investor Foresite Capital.  James ... Tarsa,s Board of Directors.  Tarsa,s existing venture capital ... Partners—all participated in the new financing round.  ...
Cached Biology Technology:CNIO researchers take part in the most comprehensive personalized medicine study performed to date 2CNIO researchers take part in the most comprehensive personalized medicine study performed to date 3Researchers develop graphene supercapacitor holding promise for portable electronics 2Researchers develop graphene supercapacitor holding promise for portable electronics 3Researchers develop graphene supercapacitor holding promise for portable electronics 4Tarsa Therapeutics Completes $28 Million Series B Financing to Advance OSTORA™ Oral Calcitonin 2Tarsa Therapeutics Completes $28 Million Series B Financing to Advance OSTORA™ Oral Calcitonin 3Tarsa Therapeutics Completes $28 Million Series B Financing to Advance OSTORA™ Oral Calcitonin 4
(Date:7/30/2014)... study of dominance in female baboons suggests that the route ... mom, and to have lots of supportive sisters. , A ... strength, but by the rank of her mother - the ... be. For this reason, dominance rank in female baboons is ... mothers are guaranteed a good spot in the pecking order, ...
(Date:7/30/2014)... The Jackson Laboratory has received a pledge of $1 ... and name the Laboratory,s new Neurobehavioral Biometry Center. ... Biometry Center will enable the Laboratory to develop a ... with the ultimate goal of accelerating the pace of ... will serve as a premier resource for the Laboratory ...
(Date:7/30/2014)... Clemson University associate professor Andrew S. Mount, performed cutting-edge ... way for novel anti-fouling paint for ships and boats ... , The team,s findings, published in Nature ... barnacles that attaches to a wide variety of surfaces ... as an underwater heavy-duty adhesive. , "In previous research, ...
Breaking Biology News(10 mins):Supportive moms and sisters boost female baboon's rank 2Supportive moms and sisters boost female baboon's rank 3Rossi Foundation pledges $1M for JAX neurobehavioral research center 2Study: Marine pest provides advances in maritime anti-fouling and biomedicine 2
... project to teach undergraduate students about network analysis, turned ... to analyze a National Basketball Association (NBA) basketball team,s ... discovered it is possible to quantify both a team,s ... in an online November issue of PLOS ONE ...
... research from Georgia Aquarium and Georgia Institute of Technology ... can be used to determine the health status of ... fish species. The study, led by Dr. Alistair Dove, ... an adjunct professor at Georgia Tech, found that the ...
... Robertson (Rob) McClung is not your typical clock-watcher. His ... based on a 24-hour period. Living organisms depend upon ... rotation and the recurring changes it imposes on the ... anticipate the changes and adapt to them by modifying ...
Cached Biology News:Basketball teams offer insights into building strategic networks 2New whale shark study used metabolomics to help understand shark and ray health 2Dartmouth research: The clocks are ticking and the climate is changing 2Dartmouth research: The clocks are ticking and the climate is changing 3Dartmouth research: The clocks are ticking and the climate is changing 4
... causing shortages in your laboratory or fellow ... cause unwanted distractions, problems and delays. • ... hard work and endeavour! Bring us your ... and market it internationally. We work under ...
... Perhaps sheer in-house demand is causing shortages ... precious antibody. This can cause unwanted distractions, ... Receive royalties for your hard work ... let us build it up,and market it ...
Topoisomerase I...
...
Biology Products: